Eczema Treatment Report

www.EczemaTreatmentReport.com

PF-04965842

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Inhibitor, Abrocitinib (PF-04965842), in Patients with Moderate to Severe Atopic Dermatitis

https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_pf_04965842_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis

https://www.bloomberg.com/press-releases/2019-09-27/pfizer-announces-positive-top-line-results-from-second-pivotal-phase-3-study-of-investigational-oral-jak1-candidate

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients with Moderate to Severe Atopic Dermatitis

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis [Completed]

https://clinicaltrials.gov/ct2/show/NCT03575871?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F09%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

DESCRIPTION:
Condition:   Dermatitis, Atopic
Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
Sponsor:   Pfizer
Completed

CLINICALTRIALS.GOV IDENTIFIER:
NCT03575871

FIRST POSTED:
Tue, 03 Jul 2018 12:00:00 EDT

LAST UPDATE POSTED:
09/23/19 07:49AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03575871?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F09%2F2019&lupd_d=14&sort=nwst

Back to top